je.st
news
Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a...
2014-01-23 08:48:30| Biotech - Topix.net
Alnylam Pharmaceuticals , Inc. , a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 study with ALN - AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin for the treatment of hemophilia and rare bleeding disorders .
Tags: a
trial
phase
clinical
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||